Enterprise Value
-50.19M
Cash
192.9M
Avg Qtr Burn
-31.81M
Short % of Float
7.83%
Insider Ownership
2.20%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ANX005 (IV) Details Huntington's disease, Brain disease | Phase 3 Initiation | |
ANX005 (IV) Details Guillian-Barre syndrome, Autoimmune disease | Phase 2/3 Data readout | |
ANX007 (IVT) Details Geographic atrophy | Phase 2 Data readout | |
ANX005 (IV) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Phase 2a Data readout | |
ANX009 Details Lupus nephritis | Phase 1b Data readout | |
ANX105 Details Autoimmune disease, Neurodegenerative disease | Phase 1 Data readout | |
ANX1502 Details Autoimmune disease | Phase 1a Data readout | |
ANX005 (IV) Details Warm autoimmune hemolytic anemia, Autoimmune disease | Failed Discontinued |